Diagnosis and treatment of multiple sclerosis: a review
MP McGinley, CH Goldschmidt, AD Rae-Grant - Jama, 2021 - jamanetwork.com
Importance Multiple sclerosis (MS) is an autoimmune-mediated neurodegenerative disease
of the central nervous system characterized by inflammatory demyelination with axonal …
of the central nervous system characterized by inflammatory demyelination with axonal …
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
DSW Lee, OL Rojas, JL Gommerman - Nature reviews Drug discovery, 2021 - nature.com
In the past 15 years, B cells have been rediscovered to be not merely bystanders but rather
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …
active participants in autoimmune aetiology. This has been fuelled in part by the clinical …
How patients with multiple sclerosis acquire disability
Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …
worsening (RAW) or progression independent of relapse activity (PIRA). This study …
Treatment of multiple sclerosis: a review
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of
the central nervous system, and the leading cause of nontraumatic neurological disability in …
the central nervous system, and the leading cause of nontraumatic neurological disability in …
Immune responses to stroke: mechanisms, modulation, and therapeutic potential
Stroke is the second leading cause of death worldwide and a leading cause of disability.
Most strokes are caused by occlusion of a major cerebral artery, and substantial advances …
Most strokes are caused by occlusion of a major cerebral artery, and substantial advances …
Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions
Summary The sphingosine 1-phosphate (S1P) signalling pathways have important and
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …
diverse functions. S1P receptors (S1PRs) have been proposed as a therapeutic target for …
Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial
Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming
available in the past years. There is a need for a reference tool compiling current data to aid …
available in the past years. There is a need for a reference tool compiling current data to aid …
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Background No treatment has consistently shown efficacy in slowing disability progression
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of …
Sphingolipid metabolism in cancer signalling and therapy
B Ogretmen - Nature Reviews Cancer, 2018 - nature.com
Sphingolipids, including the two central bioactive lipids ceramide and sphingosine-1-
phosphate (S1P), have opposing roles in regulating cancer cell death and survival …
phosphate (S1P), have opposing roles in regulating cancer cell death and survival …